Please login to the form below

CD3

This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.

Xencor’s Novartis-partnered bispecific on hold after patient deaths

CD3 is a popular domain target for bispecific antibodies as it activates T-cells to kill malignant cells. ... It’s not the first CD3-targeting bispecific to run into safety concerns.

Latest news

AbbVie enters BCMA race with Teneobio deal

TNB-383B is a bispecific antibody which targets the cluster of differentiation 3 (CD3) site as well as BCMA, which the partners hope will give it an edge over more established ... The selected anti-CD3 antibodies from TeneoSeek can be incorporated in bi-
Sanofi and Regeneron re-jig immuno-oncology deal

The two candidates selected as most promising are REGN5458 (aka BCMAxCD3), a BCMA and CD3 targeting bispecific antibody and REGN4018, a MUC16 and CD3 targeting bispecific antibody.
Regeneron’s early stage bispecific shows promise

The drug binds to CD3 on immune system T-cells and CD20 on B-cell malignancies.
Affimed rockets on $5bn-plus Roche immuno-oncology deal

ALL). A third drug from the platform –CD33/CD3 T cell engager AMV564 – has been licensed to US biotech Amphivena and is in phase I for the treatment of acute myeloid
Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding

T-Guard consists of a unique combination of toxin-conjugated monoclonal antibodies that target the CD3 and CD7 molecules on T cells and NK cells.

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Taking a lean and careful approach

Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,
Deal Watch June 2016

Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding
Pharma deals during December 2014

platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.
Deal Watch table for August 2014

187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
Pharma deals during February 2014

CD123 and CD3.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences

Shailubhai takes the helm as Tiziana focuses on developing an orally administered, anti-CD3 mAb (foalumab) drug candidate to manage non-alcoholic steatohepatitis (NASH) - a liver disease that has no treatment

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Director – Healthcare PR: Salary TBC

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

NEW FREELANCE OPPORTUNITIES!!! LONDON and HOME WORKING!: EXCELLENT DAY RATES AVAILABLE

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Senior Medical Writer: Salary TBC

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Medical Writer: Competitive salary and benefits

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Director, Medical Education: Salary TBC

PR Associate Director – Consumer Health & Beauty: Salary TBC

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Subscribe to our email news alerts

PMHub

Add my company

Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...